105 related articles for article (PubMed ID: 9416969)
1. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114).
Woynarowski JM; Napier C; Koester SK; Chen SF; Troyer D; Chapman W; MacDonald JR
Biochem Pharmacol; 1997 Dec; 54(11):1181-93. PubMed ID: 9416969
[TBL] [Abstract][Full Text] [Related]
2. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF).
Herzig MC; Arnett B; MacDonald JR; Woynarowski JM
Biochem Pharmacol; 1999 Jul; 58(2):217-25. PubMed ID: 10423161
[TBL] [Abstract][Full Text] [Related]
3. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF).
Woynarowska BA; Woynarowski JM; Herzig MC; Roberts K; Higdon AL; MacDonald JR
Biochem Pharmacol; 2000 May; 59(10):1217-26. PubMed ID: 10736422
[TBL] [Abstract][Full Text] [Related]
4. Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells.
Woynarowska BA; Roberts K; Woynarowski JM; MacDonald JR; Herman TS
Radiat Res; 2000 Oct; 154(4):429-38. PubMed ID: 11023607
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Hidalgo M; Izbicka E; Eckhardt SG; MacDonald JR; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
Anticancer Drugs; 1999 Oct; 10(9):837-44. PubMed ID: 10587294
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent.
Herzig MC; Trevino AV; Liang H; Salinas R; Waters SJ; MacDonald JR; Woynarowska BA; Woynarowski JM
Biochem Pharmacol; 2003 Feb; 65(4):503-13. PubMed ID: 12566077
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.
Kelner MJ; McMorris TC; Estes L; Wang W; Samson KM; Taetle R
Invest New Drugs; 1996; 14(2):161-7. PubMed ID: 8913837
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
[TBL] [Abstract][Full Text] [Related]
9. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells.
Faivre S; Chan D; Salinas R; Woynarowska B; Woynarowski JM
Biochem Pharmacol; 2003 Jul; 66(2):225-37. PubMed ID: 12826265
[TBL] [Abstract][Full Text] [Related]
10. Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status.
Herzig MC; Liang H; Johnson AE; Woynarowska B; Woynarowski JM
Breast Cancer Res Treat; 2002 Jan; 71(2):133-43. PubMed ID: 11883439
[TBL] [Abstract][Full Text] [Related]
11. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines.
Kelner MJ; McMorris TC; Montoya MA; Estes L; Uglik SF; Rutherford M; Samson KM; Bagnell RD; Taetle R
Cancer Chemother Pharmacol; 1999; 44(3):235-40. PubMed ID: 10453725
[TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
MacDonald JR; Muscoplat CC; Dexter DL; Mangold GL; Chen SF; Kelner MJ; McMorris TC; Von Hoff DD
Cancer Res; 1997 Jan; 57(2):279-83. PubMed ID: 9000568
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
O'Neill CF; Ormerod MG; Robertson D; Titley JC; Cumber-Walsweer Y; Kelland LR
Br J Cancer; 1996 Oct; 74(7):1037-45. PubMed ID: 8855971
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways.
Jaspers NG; Raams A; Kelner MJ; Ng JM; Yamashita YM; Takeda S; McMorris TC; Hoeijmakers JH
DNA Repair (Amst); 2002 Dec; 1(12):1027-38. PubMed ID: 12531012
[TBL] [Abstract][Full Text] [Related]
16. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents.
Gorczyca W; Gong J; Ardelt B; Traganos F; Darzynkiewicz Z
Cancer Res; 1993 Jul; 53(13):3186-92. PubMed ID: 8319228
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells.
Woynarowski JM; Woynarowska BA; Trevino AV; Salinas R; Herman TS; Waters SJ; Macdonald JR
Cancer Biol Ther; 2004 Nov; 3(11):1137-42; discussion 1143-4. PubMed ID: 15467441
[TBL] [Abstract][Full Text] [Related]
18. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.
Kelner MJ; McMorris TC; Estes L; Samson KM; Trani NA; MacDonald JR
Leukemia; 2000 Jan; 14(1):136-41. PubMed ID: 10637489
[TBL] [Abstract][Full Text] [Related]
19. Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells.
Wang W; Waters SJ; MacDonald JR; Von Hoff DD; Strodel WE; Miller AR
Anticancer Res; 2001; 21(3B):1789-94. PubMed ID: 11497260
[TBL] [Abstract][Full Text] [Related]
20. Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug.
McMorris TC
Bioorg Med Chem; 1999 May; 7(5):881-6. PubMed ID: 10400341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
